On Thursday, 05 June 2025, IMAB (NASDAQ:IMAB) presented at the Jefferies Global Healthcare Conference 2025, revealing strategic insights into its clinical pipeline. The company highlighted both promising advancements and ongoing challenges, notably in its Claudin 18.2 bispecific antibody, Giva (FT825), aimed at addressing unmet needs in gastric cancer treatment.
Key Takeaways
- IMAB is financially robust with $168.8 million to support clinical developments.
- Giva (FT825) shows promise in frontline gastric cancer therapy, with an upcoming data release at ESMO GI on July 2nd.
- The company plans further data releases for Raji and Yuli in late 2025 and early 2026.
- IMAB’s team highlighted Giva’s unique features, including high binding affinity and reduced toxicity.
Financial Results
- IMAB holds $168.8 million, ensuring funding through key clinical readouts.
- The Claudin 18.2 positive gastric cancer market is valued at $12 billion, a target for Giva’s application.
Operational Updates
- IMAB employs 25 staff, focusing on clinical efficiency within the US.
- Giva’s dose expansion is progressing rapidly, with data to be presented at ESMO GI.
- Raji’s Phase I study aims to optimize dosing to minimize liver toxicity.
- Yuli’s Phase 2 study in lung cancer is underway, with results expected soon.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.